Sagility India Ltd : Riding the US healthcare outsourcing wave

Stock Opportunities Untested - but worth a good look
1

1. Business overview

Sagility India Ltd (formerly Bermen India Pvt. Ltd.) is a healthcare-focused, technology-enabled business process management company serving primarily US-based clients in the payer and provider segments. It operates in the IT-enabled services space, offering outsourced services such as claims processing, revenue cycle management, care management and related back-office and tech-enabled workflows for US healthcare insurers and providers.

The company is effectively a play on the structural trend of US healthcare systems outsourcing non-core yet critical processes to specialized offshore vendors who can deliver at scale with better cost efficiency.

As of now, Sagility has a market cap of around â‚ą18,900 crore, with the stock trading near â‚ą40 per share, a 52-week range of â‚ą57.9 / â‚ą37.6 and a trailing P/E of about 21.6.

2. Promoters and background

Sagility was incorporated in July 2021 and is relatively young in its current listed avatar, but the underlying operations are part of a longer-standing global healthcare BPO franchise. The company is headquartered in Bengaluru and serves only US customers, where it holds about 1.23% share of the US healthcare outsourcing market as of 2023.

Promoter holding has reduced by ~16.4% in the last reported quarter, which is worth tracking closely for signalling and overhang. At the same time, the business has been deleveraging, with reported debt coming down over the last few years. Return ratios are still moderate, with last reported ROCE at ~9.6% and ROE at ~7.4%, reflecting the transition phase and heavy capital employed in goodwill/intangibles and working capital.

3. Journey so far

Although the listed history is short, the ramp-up post-2022 has been quite strong. On a consolidated basis, reported revenues have grown from about â‚ą4,218 crore in FY23 to â‚ą5,570 crore in FY25, with TTM revenues at ~â‚ą6,737 crore. Operating profit has moved from ~â‚ą1,039 crore in FY23 to â‚ą1,307 crore in FY25, with TTM operating profit tracking upwards.

Operating margins have been relatively stable in the low-20s: OPM was ~25% in FY23, ~23% in FY24 and ~23% in FY25/TTM, which is healthy for a people-intensive ITES model if they can maintain utilisation and pricing. PAT has scaled from â‚ą144 crore in FY23 to â‚ą539 crore in FY25, with TTM PAT around â‚ą850 crore, implying very strong recent profit compounding on a low base. EPS has risen from â‚ą0.75 in FY23 to â‚ą1.15 TTM, with the company yet to start meaningful dividends (payout at 0% so far).

4. Business model, segments and economics

Sagility is essentially a US healthcare-focused BPM platform: it provides end-to-end tech-enabled services for payers and providers that include claims adjudication, member enrollment, provider data management, billing, collections, clinical documentation support and other back-office plus analytics-heavy workflows.

The business is asset-light in terms of physical capex but people- and platform-heavy. Operating leverage comes from:

  • Higher seat utilisation and offshoring mix

  • Increased automation/AI in repetitive workflows

  • Cross-selling more processes to existing payer/provider clients

The company’s cost structure shows employee and operating expenses as the key line items, with depreciation and interest relatively modest compared to revenues. As utilisation improves and newer contracts scale up, incremental margins can be attractive if pricing discipline is maintained.

5. Industry tailwinds

US healthcare is a large and structurally growing end-market with increasing complexity, regulatory changes (HIPAA, ACA, etc.), and rising cost pressures. This combination structurally favours specialist offshore providers who can:

  • Take over non-core but mission-critical processes

  • Offer 24x7 operations at lower cost

  • Bring tech tools (workflow automation, analytics, AI/ML)

The company’s 1.23% market share in US healthcare outsourcing suggests a long runway if it can gain share from both in-house operations and smaller local vendors. Being fully focused on US healthcare also means deeper domain expertise, albeit with client and geography concentration risk.

6. Financial snapshot

Key snapshot (consolidated, Screener TTM):

  • Market cap: ~â‚ą18,890 crore

  • Price: ~â‚ą40

  • P/E: ~21.6

  • Book value: ~â‚ą19

  • Dividend yield: ~0.12%

  • ROCE: ~9.6%

  • ROE: ~7.4%

Recent quarterly numbers show:

  • Quarterly sales around â‚ą1,971 crore with ~35.7% YoY growth

  • Quarterly PAT of ~â‚ą268 crore with ~34.6% YoY growth

This combination of mid-30s topline growth and similar profit growth, at a low-20s P/E multiple, is interesting, but return ratios need to keep improving from single digits as the business matures.

7. Balance sheet and cash flows

On the balance sheet side, equity capital has risen from ~₹1,919 crore in FY22 to ~₹4,679 crore in FY25, with reserves moving from ~₹2,108 crore to ~₹3,657 crore over the same period. Total assets have been in the ~₹10,000–10,900 crore range, roughly matching total liabilities, reflecting the expanded capital structure post corporate actions.

The asset base is largely composed of fixed assets plus a sizable chunk of “other assets” and working capital (receivables, cash, etc.), consistent with a service business with global clients. Net debt has trended lower as the company has reduced borrowings.

Cash flow-wise:

  • Operating cash flow turned strongly positive from FY23 onwards (â‚ą857 crore in FY23, â‚ą973 crore in FY24, and â‚ą1,214 crore in FY25)

  • Investing cash flows have been negative due to capex/investments

  • Financing cash flows show debt reduction and some capital structure changes

Working capital efficiency appears reasonable: debtor days have improved from 366 in FY22 to low-90s (92–91) in FY23–24, and working capital days are in low double digits or slightly negative, indicating decent cash conversion.

8. Ratios and return profile

ROCE has improved from ~5% to ~10% over FY23–25, but still trails best-in-class IT services peers that operate in the mid-teens to high-20s. ROE has also moved up yet remains in high single digits, again reflecting early-stage integration and capital structure, plus goodwill-heavy balance sheet.

Key levers for further improvement:

  • Sustaining >15–20% revenue growth

  • Maintaining OPM in low-to-mid-20s

  • Improving asset turns and controlling working capital

If these come together, there is room for ROCE/ROE to migrate into the mid-teens over time.

9. Peer snapshot

On Screener’s peer table, Sagility sits alongside IT and ITES names like L&T Technology Services, Inventurus (Newgen-like), Tata Technologies, Netweb, Affle, and Cyient:

  • Sagility: P/E ~21.6, ROCE ~9.6%, sales growth ~35.7%

  • Affle: P/E ~42.8, ROCE ~16.8%

  • Cyient: P/E ~18.3, ROCE ~16.6%

  • L&T Technology: P/E ~27.4, ROCE ~28.3%

So Sagility trades at a discount to some higher-ROCE digital/IT names but with similar or higher near-term growth, reflecting its shorter track record, client concentration and lower return ratios.

10. Recent developments

Recent disclosures show:

  • Intimation of investor/analyst meetings at IIFL and Kotak in February 2026, indicating active engagement with the market

  • Appointment of a new Group CFO, Srinivas Rathnam Mattapalli (30+ years’ experience), as KMP in February 2026, which could be important for capital allocation and margin discipline

  • Regular concall transcripts and PPTs available from 2024–2026 for deeper dive on strategy, client concentration, and margin levers

These steps suggest increasing maturity in investor communication and governance processes.

11. Key risks

Some early observations on risks:

  • Client and geography concentration (only US healthcare customers)

  • Moderate ROCE/ROE relative to IT peers; needs sustained improvement

  • Promoter holding reduction by ~16.4% in the last quarter may create overhang and raises questions on long-term alignment

  • People-intensive delivery model in a competitive ITES market, with wage inflation and pricing pressure risks

  • Regulatory and policy risks tied to US healthcare and outsourcing

12. What to track going forward

Personally, if I treat this as a potential “compounder in the making” in US healthcare outsourcing, the key things I would track are:

  • Sustainability of 15–20%+ revenue growth over the next 3–5 years

  • Trajectory of operating margins (can they hold or expand beyond ~23%?)

  • Improvement in ROCE/ROE towards mid-teens

  • Promoter/major shareholder actions (further stake sales or stabilisation)

  • Cash flow consistency versus reported earnings and any large acquisitions

If these move in the right direction, Sagility could evolve from “interesting growth story” to a steadier healthcare BPM compounder with a long runway.

Disclaimer
Small and midcap IT/ITES and relatively new listings carry higher risks due to limited listed history, client concentration and evolving governance. This post is for discussion and educational purposes only and is not investment advice. Please do your own research and consult a SEBI-registered advisor before making any investment decisions.

My holding: 1.5%

2 Likes
2

Just to add most of promoter selling was bought by institutions(promoter reduced 32% from march to december, fii increased by 7% and dii by 14%, retail by 11% and number of shareholders increased by 60%) and earlier their shares were pledged 100% which also got removed when they sold

1 Like
3

I have the following doubts:

  1. can it be compared with IT companies? are the providing software development ?

  2. It is similar to Medi Assist of India ( I mean the services provided)

  3. How AI can disrupt the operations and move that back to US

Kindly help

Disc: keenly studying

4

Thanks for starting this thread. For a Peer Analysis I think the closest Peer would be IKS.

2 Likes
5

@Balaji1974

1. Can Sagility be compared with IT companies? Are they providing software development?

Sagility is best thought of as a healthcare‑focused digital operations / BPM company providing tech‑enabled services to US payers and providers. Its core offerings are:

  • Claims processing, enrollment, payment integrity

  • Revenue cycle management (billing, collections, denials management)

  • Clinical and member support, contact-center work, analytics and automation around these flows

They use technology, automation, analytics and AI as enablers, but their primary revenue is from services, not from building and selling stand‑alone software products like a typical IT services or SaaS firm. So:

  • You can loosely group them with IT/ITeS/BPM for valuation and peer comparison (like healthcare BPO / RCM players).

  • But they are not a pure software development shop like a TCS/Infosys; they are closer to a specialised healthcare BPO with strong tech and domain depth.

2. Is it similar to Medi Assist in India?

There are similarities and differences.

Similarities:

  • Both live in the healthcare & insurance ecosystem and handle non‑clinical, administrative workflows around claims, enrollment, member/hospital interactions, etc.

  • Both are “intermediary operators” rather than insurers or hospitals themselves, and both sell efficiency, cost savings and better process control.

Differences:

  • Medi Assist is a TPA in India, tied to Indian health insurers, hospitals and policyholders, with a large hospital network and focus on cashless claims and TPA services under Indian regulations.

  • Sagility is a healthcare BPM provider to US payers/providers, operating from India and other locations to serve US health insurance plans, PBMs and hospital systems.

  • Medi Assist sits legally as a “third party administrator” under the Indian insurance framework; Sagility is more of an outsourced operations/RCM partner under US healthcare and HIPAA/CMS rules.

So yes, in spirit they are analogous (both monetise healthcare administrative complexity), but geography, regulation and specific workflows differ.

3. How can AI disrupt operations and move work back to the US?

AI is already changing healthcare BPO, but it does not automatically mean all work goes back onshore.

Where AI helps firms like Sagility:

  • Automating repetitive tasks in claims, enrollment, document handling, coding, and denial management.

  • Using predictive analytics in revenue cycle to reduce denials and speed up collections.

  • Conversational AI for member/customer support, reducing human call‑center load.

  • Better compliance and fraud/risk monitoring using anomaly detection.

These capabilities allow offshore BPM players to handle more work per FTE, improve margins and become more strategic partners, which actually strengthens the offshoring model in the medium term.

What could push work back to the US over the long term:

  • If AI + automation become so powerful and plug‑and‑play that US payers/providers can deploy these tools in‑house with minimal labor, the labour‑arbitrage advantage of India shrinks.

  • Regulatory pressure, data residency rules, or political backlash against offshoring could combine with AI tools to justify more in‑house automation in the US.

  • Highly standardised, rules‑based processes (simple claims, basic member queries) are the most vulnerable to being fully automated onshore.

However, the complex, judgment‑heavy, exception‑handling part of operations, multi‑system integrations, and end‑to‑end BPaaS still favour specialised vendors with domain + tech + process expertise and that’s exactly where firms like Sagility are positioning themselves.

6 Likes